Exome sequencing reveals frequent inactivating mutations in ARID1A, ARID1B, ARID2 and ARID4A in microsatellite unstable colorectal cancer: ARID mutations in MSI CRC
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
ARID1A has been identified as a novel tumor suppressor gene in ovarian cancer and subsequently in various other tumor types. ARID1A belongs to the ARID domain containing gene family, which comprises of 15 genes involved, for example, in transcriptional regulation, proliferation and chromatin remodeling. In this study, we used exome sequencing data to analyze the mutation frequency of all the ARID domain containing genes in 25 microsatellite unstable (MSI) colorectal cancers (CRCs) as a first systematic effort to characterize the mutation pattern of the whole ARID gene family. Genes which fulfilled the selection criteria in this discovery set (mutations in at least 4/25 [16%] samples, including at least one nonsense or splice site mutation) were chosen for further analysis in an independent validation set of 21 MSI CRCs. We found that in addition to ARID1A, which was mutated in 39% of the tumors (18/46), also ARID1B (13%, 6/46), ARID2 (13%, 6/46) and ARID4A (20%, 9/46) were frequently mutated. In all these genes, the mutations were distributed along the entire length of the gene, thus distinguishing them from typical MSI target genes previously described. Our results indicate that in addition to ARID1A, other members of the ARID gene family may play a role in MSI CRC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863
An integrated map of genetic variation from 1,092 human genomes
The 1000 Genomes Project Consortium (2012) · Nature · doi:10.1038/nature11632 · Cited by 7,711
dbSNP: the NCBI database of genetic variation
Sherry, S. T. (2001) · Nucleic Acids Research · doi:10.1093/nar/29.1.308 · Cited by 7,502
A landscape of driver mutations in melanoma
Hodis, E., Watson, I. R., Kryukov, G. V., Arold, S. T., Imielinski, M., Theurillat, J.-P., Nickerson, E., Auclair, D., Li, L., Place, C., et al. (2012) · Cell · doi:10.1016/j.cell.2012.06.024 · Cited by 2,610 · cited 1×
“ARID2 mutations have also been reported in pancreatic cancer (2%) and melanoma (7%).(41,42) In our data, ARID2 was mutated in 6/46 (13%) samples.”
BackgroundPancreatic cancer genomes reveal aberrations in axon guidance pathway genes
Initiative, A. P. C. G., Biankin, A. V., Waddell, N., Kassahn, K. S., Gingras, M.-C., Muthuswamy, L. B., Johns, A. L., Miller, D. K., Wilson, P. J., Patch, A.-M., et al. (2012) · Nature · doi:10.1038/nature11547 · Cited by 2,058 · cited 1×
“ARID2 mutations have also been reported in pancreatic cancer (2%) and melanoma (7%).(41,42) In our data, ARID2 was mutated in 6/46 (13%) samples.”
BackgroundARID1A Mutations in Endometriosis-Associated Ovarian Carcinomas
Wiegand, K. C., Shah, S. P., Al-Agha, O. M., Zhao, Y., Tse, K., Zeng, T., Senz, J., McConechy, M. K., Anglesio, M. S., Kalloger, S. E., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1008433 · Cited by 1,712 · cited 1×
“This is similar to what has previously been observed in clear cell and endometrioid ovarian cancer, where 17 out of 152 tumors studied (11%) had two confirmed somatic mutations.(7) ARID1A and TP53 mutations have been suggested to be mutually exclusive in several cancer types.”
ResultRAF/RAS oncogenes and mismatch-repair status
Rajagopalan, H., Bardelli, A., Lengauer, C., Kinzler, K. W., Vogelstein, B., & Velculescu, V. E. (2002) · Nature · doi:10.1038/418934a · Cited by 1,224 · cited 1×
“in MSI CRC have been identified, the best characterized being the v-raf murine sarcoma viral oncogene homolog B1 (BRAF) V600E with mutation frequency of nearly 30%.(4,5) With next-generation sequencing methods, however, it is now possible to perform more comprehensive mutation profiling of these tumors.”
BackgroundShain, A. H., Giacomini, C. P., Matsukuma, K., Karikari, C. A., Bashyam, M. D., Hidalgo, M., Maitra, A., & Pollack, J. R. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1114817109 · Cited by 221
Cited by
Prioritization of cancer therapeutic targets using CRISPR–Cas9 screens
Behan, F. M., Iorio, F., Picco, G., Gonçalves, E., Beaver, C. M., Migliardi, G., Santos, R., Rao, Y., Sassi, F., Pinnelli, M., et al. (2019) · Nature · doi:10.1038/s41586-019-1103-9 · Cited by 1,338
ARID1A loss impairs enhancer-mediated gene regulation and drives colon cancer in mice
Mathur, R., Alver, B. H., San Roman, A. K., Wilson, B. G., Wang, X., Agoston, A. T., Park, P. J., Shivdasani, R. A., & Roberts, C. W. M. (2017) · Nature Genetics · doi:10.1038/ng.3744 · Cited by 360
The emerging roles of ARID1A in tumor suppression
Wu, R.-C., Wang, T.-L., & Shih, I.-M. (2014) · Cancer Biology & Therapy · doi:10.4161/cbt.28411 · Cited by 261
Microsatellite instability: an update
Yamamoto, H., & Imai, K. (2015) · Archives of Toxicology · doi:10.1007/s00204-015-1474-0 · Cited by 247
Chromatin-Remodeling-Factor ARID1B Represses Wnt/β-Catenin Signaling
Vasileiou, G., Ekici, A. B., Uebe, S., Zweier, C., Hoyer, J., Engels, H., Behrens, J., Reis, A., & Hadjihannas, M. V. (2015) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2015.08.002 · Cited by 81
“Interestingly, frequent inactivating mutations in ARID1B were also reported in colorectal cancers driven by aberrant Wnt/b-catenin signaling, and ARID1B-mutated medulloblastomas show activation of the Wnt/b-catenin pathway.(7,26) By using individuals with ID who are harboring ARID1B loss-of-function mutations as a dep…”
Background
Metadata
- Authors
- Cajuso, T., Hänninen, U. A., Kondelin, J., Gylfe, A. E., Tanskanen, T., Katainen, R., Pitkänen, E., Ristolainen, H., Kaasinen, E., Taipale, M., Taipale, J., Böhm, J., Renkonen-Sinisalo, L., Mecklin, J.-P., Järvinen, H., Tuupanen, S., Kilpivaara, O., & Vahteristo, P.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2014-01-13
- Volume
- 135
- Issue
- 3
- Pages
- 611-623
- ISSN
- 0020-7136 (ISSN-L)
- OpenAlex
- W1596380405
- Cited by
- 125
- References
- 9
- FWCI
- 8.51
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Exome sequencing reveals frequent inactivating mutations in ARID1A, ARID1B, ARID2 and ARID4A in microsatellite unstable colorectal cancer: ARID mutations in MSI CRC. https://app.cochat.ai/papers/10.1002/ijc.28705
- The paper
- Cajuso, T., Hänninen, U. A., Kondelin, J., Gylfe, A. E., Tanskanen, T., Katainen, R., Pitkänen, E., Ristolainen, H., Kaasinen, E., Taipale, M., Taipale, J., Böhm, J., Renkonen-Sinisalo, L., Mecklin, J.-P., Järvinen, H., Tuupanen, S., Kilpivaara, O., & Vahteristo, P. (2014). Exome sequencing reveals frequent inactivating mutations in ARID1A, ARID1B, ARID2 and ARID4A in microsatellite unstable colorectal cancer: ARID mutations in MSI CRC. International Journal of Cancer. https://doi.org/10.1002/ijc.28705
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.